@article{Zhao2024, 
author = {Liyuan Zhao and Zixuan Yang and Minhui Zheng and Lei Shi and Mengyun Gu and Gang Liu and Feng Miao and Yan Chang and Fanghua Huang and Naping Tang},
title = {Recombinant adeno-associated virus 8 vector in gene therapy: Opportunities and challenges},
year = {2024},
journal = {Genes & Diseases},
volume = {11},
number = {1},
pages = {283-293},
keywords = {AAV8, Adeno-associated virus, Gene therapy, Primates, Recombinant, Rodents},
url = {https://www.sciopen.com/article/10.1016/j.gendis.2023.02.010},
doi = {10.1016/j.gendis.2023.02.010},
abstract = {In recent years, significant breakthroughs have been made in the field of gene therapy. Adeno-associated virus (AAV) is one of the most promising gene therapy vectors and a powerful tool for delivering the gene of interest. Among the AAV vectors, AAV serotype 8 (AAV8) has attracted much attention for its efficient and stable gene transfection into specific tissues. Currently, recombinant AAV8 has been widely used in gene therapy research on a variety of diseases, including genetic diseases, cancers, autoimmune diseases, and viral diseases. This paper reviewed the applications and challenges of using AAV8 as a vector for gene therapy, with the aim of providing a valuable resource for those pursuing the application of viral vectors in gene therapy.}
}